288 related articles for article (PubMed ID: 25867064)
1. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.
Zhu X; Shen H; Yin X; Long L; Xie C; Liu Y; Hui L; Lin X; Fang Y; Cao Y; Xu Y; Li M; Xu W; Li Y
Oncogene; 2016 Jan; 35(3):323-32. PubMed ID: 25867064
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
4. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
5. miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma.
Liu M; Wang J; Huang H; Hou J; Zhang B; Wang A
Biochem Biophys Res Commun; 2013 Nov; 441(2):364-70. PubMed ID: 24148247
[TBL] [Abstract][Full Text] [Related]
6. miR-326 regulates EMT and metastasis of endometrial cancer through targeting TWIST1.
Liu W; Zhang B; Xu N; Wang MJ; Liu Q
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3787-3793. PubMed ID: 28975990
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer.
Yu Y; Zhao Y; Sun XH; Ge J; Zhang B; Wang X; Cao XC
Oncotarget; 2015 Oct; 6(33):34423-36. PubMed ID: 26460733
[TBL] [Abstract][Full Text] [Related]
8. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
9. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
10. MiR-15a-3p suppresses the growth and metastasis of ovarian cancer cell by targeting Twist1.
Fan B; Chen LP; Yuan YH; Xiao HN; Lv XS; Xia ZY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1934-1946. PubMed ID: 30915736
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
12. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.
Yoshino H; Yonemori M; Miyamoto K; Tatarano S; Kofuji S; Nohata N; Nakagawa M; Enokida H
Oncotarget; 2017 Mar; 8(13):20881-20894. PubMed ID: 28152509
[TBL] [Abstract][Full Text] [Related]
13. CXCL11 mediates TWIST1-induced angiogenesis in epithelial ovarian cancer.
Koo YJ; Kim TJ; Min KJ; So KA; Jung US; Hong JH
Tumour Biol; 2017 May; 39(5):1010428317706226. PubMed ID: 28488542
[TBL] [Abstract][Full Text] [Related]
14. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
15. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
16. Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells.
Wang L; Mezencev R; Švajdler M; Benigno BB; McDonald JF
Gynecol Oncol; 2014 Jul; 134(1):96-103. PubMed ID: 24802724
[TBL] [Abstract][Full Text] [Related]
17. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
18. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer.
Li RH; Chen M; Liu J; Shao CC; Guo CP; Wei XL; Li YC; Huang WH; Zhang GJ
Cell Death Dis; 2018 Dec; 9(12):1171. PubMed ID: 30518916
[TBL] [Abstract][Full Text] [Related]
20. MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist.
Sun X; Cui M; Zhang A; Tong L; Wang K; Li K; Wang X; Sun Z; Zhang H
J Exp Clin Cancer Res; 2016 Jan; 35():10. PubMed ID: 26762267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
